Maridea Wealth Management LLC Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Maridea Wealth Management LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 4th quarter, Holdings Channel.com reports. The firm bought 4,533 shares of the biotechnology company’s stock, valued at approximately $551,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its stake in shares of Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after acquiring an additional 12,000 shares during the period. Geode Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of Sarepta Therapeutics in the 4th quarter worth approximately $3,829,000. Summit Partners Public Asset Management LLC boosted its stake in shares of Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after purchasing an additional 116,800 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Sarepta Therapeutics by 19.1% during the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company’s stock worth $8,228,000 after buying an additional 10,815 shares during the period. Institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on SRPT shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. HC Wainwright restated a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, March 19th. Royal Bank of Canada decreased their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Deutsche Bank Aktiengesellschaft dropped their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Finally, Scotiabank reduced their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $167.41.

Sarepta Therapeutics Trading Down 1.9 %

NASDAQ SRPT opened at $70.41 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $6.83 billion, a P/E ratio of 56.33 and a beta of 0.79. The business has a fifty day simple moving average of $102.66 and a 200 day simple moving average of $116.06. Sarepta Therapeutics, Inc. has a 12 month low of $69.81 and a 12 month high of $173.25.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.